Plimoth Trust Co. LLC Has $515,000 Stock Holdings in Danaher Corporation $DHR

Plimoth Trust Co. LLC lifted its holdings in shares of Danaher Corporation (NYSE:DHR) by 50.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,605 shares of the conglomerate’s stock after purchasing an additional 870 shares during the period. Plimoth Trust Co. LLC’s holdings in Danaher were worth $515,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. GHP Investment Advisors Inc. boosted its position in shares of Danaher by 396.0% during the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 99 shares in the last quarter. Sierra Ocean LLC lifted its holdings in shares of Danaher by 116.9% in the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock worth $29,000 after purchasing an additional 76 shares in the last quarter. Smallwood Wealth Investment Management LLC acquired a new stake in Danaher in the 1st quarter valued at $31,000. Dunhill Financial LLC lifted its stake in shares of Danaher by 68.4% in the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate’s stock valued at $34,000 after buying an additional 67 shares in the last quarter. Finally, Costello Asset Management INC acquired a new position in shares of Danaher during the first quarter valued at about $41,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Up 2.2%

Shares of NYSE DHR opened at $215.05 on Monday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The stock has a market capitalization of $153.98 billion, a PE ratio of 45.75, a P/E/G ratio of 3.06 and a beta of 0.77. Danaher Corporation has a one year low of $171.00 and a one year high of $279.41. The business’s fifty day moving average price is $200.19 and its 200-day moving average price is $197.24.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.64 by $0.16. The business had revenue of $5.94 billion for the quarter, compared to analysts’ expectations of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm’s quarterly revenue was up 3.4% compared to the same quarter last year. During the same period in the previous year, the business posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities research analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher’s dividend payout ratio (DPR) is 27.23%.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director owned 20,751 shares of the company’s stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 11.20% of the company’s stock.

Analyst Upgrades and Downgrades

DHR has been the topic of several recent research reports. Evercore ISI dropped their price target on shares of Danaher from $230.00 to $226.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 8th. Barclays reaffirmed an “overweight” rating and set a $225.00 target price (up previously from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. UBS Group lowered their price target on Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a research report on Wednesday, July 23rd. Bank of America cut their price target on shares of Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a report on Monday, September 22nd. Finally, Wells Fargo & Company decreased their price target on Danaher from $210.00 to $205.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 23rd. Seventeen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and an average target price of $245.91.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.